Full Text View
Tabular View
No Study Results Posted
Related Studies
Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens
This study has been completed.
Study NCT00470210   Information provided by Germans Trias i Pujol Hospital

First Received on May 4, 2007.   Last Updated on April 15, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Hepatitis
Hepatitis A
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Liver Diseases
Picornaviridae Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Ribavirin (Copegus®) 1600 mg/day
Epoetin β (450 UI/kg/week)
Additional drug interventions recognized in this trial
Epoetin Alfa
Interferon-alpha
Peginterferon alfa-2a
Ribavirin
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antiviral Agents
Hematinics
Hematologic Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Germans Trias i Pujol Hospital
Fundacio Lluita Contra la SIDA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services